| The electrophysiologic basis for the use of amiodarone for treatment of cardiac arrhythmias. | |
| | |
MedLine Citation:
|
PMID: 6192414 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The electrophysiologic basis for the use of amiodarone in the treatment of cardiac arrhythmias is outlined, with reference to studies in isolated cardiac tissues, whole animal, and human studies. Amiodarone appears to have the distinctive property of directly prolonging action potential duration (and hence refractory periods) in nearly all cardiac tissues. Independent of its effects on refractory periods, conduction may also be impaired in the His-Purkinje system, possibly due to depression of phase 0 of the action potential. Sinus node and atrial automaticity, as well as that arising from diseased Purkinje fibers, may be depressed. Normal ventricular escape pacemakers appear relatively unaffected, however. A nonspecific anti-adrenergic action may contribute to its observed effects. These electrophysiological effects are more obvious and predictable after several weeks of oral treatment than after intravenous administration, suggesting a time-dependent mechanism of action. The drug appears well suited to the prevention of enhanced automaticity in the ventricle and re-entry throughout the heart, and its frequent clinical success in a broad spectrum of cardiac arrhythmias attests to this. Unwanted side effects include sinus node depression, His-Purkinje conduction delay or block, and ventricular arrhythmias enhanced by QT prolongation. However, the frequency of clinically significant examples of unwanted arrhythmic effects appears to be acceptably low. |
| | |
Authors:
|
A W Hamer; W J Mandel; C A Zaher; H S Karagueuzin; T Peter |
Related Documents
:
|
67724 - What does the symptom "palpitation" mean? - correlation between symptoms and the presen... 1427114 - Clinical evaluation of the patient with ventricular arrhythmia. 3878194 - Diagnosis and treatment of cardiac arrhythmias. 2122984 - Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug the... 21641364 - Interleukin 33 and st2 in non-st-elevation myocardial infarction: comparison with globa... 18319234 - Coronary stenosis treated by percutaneous angioplasty in a patient with dermatomyositis. |
Publication Detail:
|
Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Pacing and clinical electrophysiology : PACE Volume: 6 ISSN: 0147-8389 ISO Abbreviation: Pacing Clin Electrophysiol Publication Date: 1983 Jul |
Date Detail:
|
Created Date: 1983-09-23 Completed Date: 1983-09-23 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7803944 Medline TA: Pacing Clin Electrophysiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 784-94 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Action Potentials
/
drug effects Amiodarone / administration & dosage, adverse effects, therapeutic use* Animals Arrhythmias, Cardiac / drug therapy* Benzofurans / therapeutic use* Dogs Electrocardiography Humans Sinoatrial Node / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Benzofurans; 1951-25-3/Amiodarone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Use of the contralateral subclavian vein for placement of atrial electrodes in chronically VVI paced...
Next Document: Atrial premature beats with variable return cycle lengths--a clue to sinus node re-entry?